Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BERRY GLOBAL GROUP, INC.BERY · Entity 80192 | Director | November 25, 2023 | November 28, 2023 |
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Chief Financial Officer | May 11, 2026 | May 12, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BERRY GLOBAL GROUP, INC.
Report date November 25, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,728 |
Reported balance
After 2023-11-25 transaction · row 1
1 source rowRow 1 · 2023-11-25 · Exercise / conversion · Acquired 1,970 · Balance 4,728 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,393 |
Reported balance
After 2023-11-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-25 · Exercise / conversion · Disposed 1,970 · Balance 1,393 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023.
Edwards Lifesciences Corp
Report date May 11, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,740 |
Ending reported balance
After 2026-05-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-11 · Exercise / conversion · Acquired 19,830 · Balance 57,744 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Row 2 · 2026-05-11 · Tax withholding · Disposed 11,004 · Balance 46,740 |
| Performance RightsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-11 · Exercise / conversion · Disposed 19,830 · Balance 0 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2: These Performance Rights expire on May 10, 2030. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 266,318 |
Reported balance
Holding disclosure · report date 2026-05-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 266,318 |
Filing footnotes · ownership attribution and instrument terms
F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
F2: These Performance Rights expire on May 10, 2030.
ILLUMINA, INC.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,143 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 113 · Balance 11,143 F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2023 Filed Nov 22, 2023 21:56 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantDirector Stock Option (Right to Buy) · Derivative | 2,823 | $0.00 Strike: $64.62 | $0.00 |
DisclosureSEC source: 0001378992-23-000112 · form4.xml · derivative · entry 2 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,235 Underlying: Common Stock · 2,823 shares Expires 2033-11-20 F3 · derivative.exercise_date: Granted under the 2015 Long-Term Incentive Plan. Options vest in full on the first anniversary of the grant date. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:56 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantRestricted Stock Units · Derivative | 1,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001378992-23-000112 · form4.xml · derivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,363 Underlying: Common Stock · 1,393 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. Granted under the 2015 Long-Term Incentive Plan. F2 · derivative.exercise_date: The restricted stock units vest in full on the first anniversary of the grant date. Shares of BERY common stock will be delivered to the reporting person within 60 days following the date on which the restricted stock units vest. F2 · derivative.expiration_date: The restricted stock units vest in full on the first anniversary of the grant date. Shares of BERY common stock will be delivered to the reporting person within 60 days following the date on which the restricted stock units vest. Read SEC document |
| October 31, 2023 Filed Oct 31, 2023 21:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,255 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-009845 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,525 Underlying: Common Stock · 7,255 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2023 Filed Oct 31, 2023 21:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,255 | $62.66 | $454,568.55 |
DisclosureSEC source: 0001225208-23-009845 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.40 to $63.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 31, 2023 Filed Oct 31, 2023 21:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,255 | $36.75 | $266,621.25 |
DisclosureSEC source: 0001225208-23-009845 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| September 29, 2023 Filed Sep 29, 2023 20:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,255 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-009087 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,780 Underlying: Common Stock · 7,255 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2023 Filed Sep 29, 2023 20:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,255 | $69.54 | $504,527.21 |
DisclosureSEC source: 0001225208-23-009087 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.21 to $70.08. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 29, 2023 Filed Sep 29, 2023 20:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,255 | $36.75 | $266,621.25 |
DisclosureSEC source: 0001225208-23-009087 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,255 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-008596 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,035 Underlying: Common Stock · 7,255 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,255 | $77.79 | $564,366.45 |
DisclosureSEC source: 0001225208-23-008596 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,255 | $36.75 | $266,621.25 |
DisclosureSEC source: 0001225208-23-008596 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| July 31, 2023 Filed Jul 31, 2023 21:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,255 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-007787 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,290 Underlying: Common Stock · 7,255 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2023 Filed Jul 31, 2023 21:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,255 | $84.35 | $611,959.25 |
DisclosureSEC source: 0001225208-23-007787 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| July 31, 2023 Filed Jul 31, 2023 21:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,255 | $36.75 | $266,621.25 |
DisclosureSEC source: 0001225208-23-007787 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 21:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,255 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-007036 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,545 Underlying: Common Stock · 7,255 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 21:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,255 | $93.27 | $676,673.85 |
DisclosureSEC source: 0001225208-23-007036 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 21:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,255 | $36.75 | $266,621.25 |
DisclosureSEC source: 0001225208-23-007036 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| June 01, 2023 Filed Jun 7, 2023 00:31 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018079 · form4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,507 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 17, 2023 Filed May 17, 2023 23:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 8,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-006019 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 266,318 Read SEC document |
| May 17, 2023 Filed May 17, 2023 23:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 8,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-006019 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,248 Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 11,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005913 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,825 Underlying: Common Stock · 11,825 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 72,900 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005913 · doc4.xml · derivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,900 Underlying: Common Stock · 72,900 shares Expires 2030-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 9,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005913 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,744 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 80,700 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-005755 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,700 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 64,119 | $88.36 | $5,665,618.96 |
DisclosureSEC source: 0001225208-23-005755 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,294 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $87.89 to $88.88 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 16,581 | $89.22 | $1,479,385.01 |
DisclosureSEC source: 0001225208-23-005755 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,413 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $88.89 to $89.44 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2023 Filed May 11, 2023 22:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 80,700 | $35.20 | $2,840,373.69 |
DisclosureSEC source: 0001225208-23-005755 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,674 | $88.74 | $148,550.76 |
DisclosureSEC source: 0001225208-23-005618 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,294 Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 6,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005618 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,663 Underlying: Common Stock · 6,062 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 3,004 | $88.74 | $266,574.96 |
DisclosureSEC source: 0001225208-23-005618 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,968 Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005618 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 04, 2023 Filed May 5, 2023 01:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 441 | $88.10 | $38,852.10 |
DisclosureSEC source: 0001225208-23-005436 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,910 Read SEC document |
| May 03, 2023 Filed May 5, 2023 01:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 433 | $87.81 | $38,021.73 |
DisclosureSEC source: 0001225208-23-005436 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,351 Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 01:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 335 | $78.51 | $26,300.85 |
DisclosureSEC source: 0001225208-23-002469 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,784 Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002275 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,119 F1 · shares: These restricted stock units were granted on February 16, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| November 26, 2022 Filed Nov 29, 2022 21:58 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | Exercise / conversionRestricted Stock Units · Derivative | 1,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-021009 · doc1.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,970 Underlying: Common Stock · 1,091 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: The award was granted on November 29, 2021 and vested in full on November 26, 2022. F3 · derivative.expiration_date: The award was granted on November 29, 2021 and vested in full on November 26, 2022. Read SEC document |
| November 26, 2022 Filed Nov 29, 2022 21:58 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | Exercise / conversionCommon Stock | 1,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-021009 · doc1.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 18:03 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantDirector Stock Option (Right to Buy) · Derivative | 3,415 | $0.00 Strike: $57.18 | $0.00 |
DisclosureSEC source: 0001567619-22-020974 · doc1.xml · derivative · entry 2 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,412 Underlying: Common Stock · 3,415 shares Expires 2032-11-25 F3 · derivative.exercise_date: Granted under the 2015 Long-Term Incentive Plan. Options vest in full on the first anniversary of the grant date. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 18:03 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantRestricted Stock Units · Derivative | 1,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-020974 · doc1.xml · derivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,061 Underlying: Common Stock · 1,970 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. Granted under the 2015 Long-Term Incentive Plan. F2 · derivative.exercise_date: The restricted stock units vest in full on the first anniversary of the grant date. Shares of BERY common stock will be delivered to the reporting person within 60 days following the date on which the restricted stock units vest. F2 · derivative.expiration_date: The restricted stock units vest in full on the first anniversary of the grant date. Shares of BERY common stock will be delivered to the reporting person within 60 days following the date on which the restricted stock units vest. Read SEC document |
| August 09, 2022 Filed Feb 13, 2023 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 13,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-001811 · doc5.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 257,822 Read SEC document |
| August 09, 2022 Filed Feb 13, 2023 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 13,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-001811 · doc5.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,178 Read SEC document |
| May 17, 2022 Filed May 18, 2022 01:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,953 | $95.93 | $187,351.29 |
DisclosureSEC source: 0001225208-22-007142 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,261 Read SEC document |
| May 08, 2022 Filed May 11, 2022 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 14,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006812 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,831 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 08, 2022 Filed May 11, 2022 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 8,728 | $100.52 | $877,338.56 |
DisclosureSEC source: 0001225208-22-006812 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,214 Read SEC document |
| May 08, 2022 Filed May 11, 2022 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 14,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006812 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2022 Filed May 11, 2022 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 772 | $100.52 | $77,601.44 |
DisclosureSEC source: 0001225208-22-006812 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,111 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 441 | $105.93 | $46,715.13 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,883 Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · derivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 40,600 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,600 Underlying: Common Stock · 40,600 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,324 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.